Journal
CLINICAL NUCLEAR MEDICINE
Volume 43, Issue 10, Pages E346-E351Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000002219
Keywords
DOTATATE; PRRT; RrDTC
Funding
- Medical Faculty of the University of Muenster
Ask authors/readers for more resources
Introduction Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by Ga-68/Lu-177-DOTATATE could evolve as a novel theranostic option. Methods Five RrDTC patients with limited further therapeutic options and documented expression of SSRT using Ga-68-DOTATATE-PET/CT received 2 to 4 cycles of PRRT with Lu-177-DOTATATE. Response to therapy was assessed by thyroglobulin (Tg) and morphological and metabolic criteria based on interim and follow-up Ga-68-DOTATATE-PET/CTs. Analysis was performed on a per-patient basis. Results In the post-therapy evaluation, only one out of five patients showed a partial response, whereas three patients had a progressive disease. One patient had discordant findings between stable imaging results albeit rising Tg levels. Conclusion In this case study of five patients, Lu-177-DOTATATE therapy showed only heterogeneous response and efficacy in RrDTC patients despite good lesional uptake in pre-therapeutic PET.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available